medigraphic.com
ISSN 1561-302X (Impreso)

2015, Número 1

<< Anterior Siguiente >>

Rev cubana med 2015; 54 (1)


La denervación renal, un hito en la terapia de la hipertensión arterial

Arredondo BA, Pons VR

Idioma: Español
Referencias bibliográficas: 30
Paginas: 67-73
Archivo PDF: 105.69 Kb.


RESUMEN

La hipertensión arterial es una considerable amenaza mundial y un factor de riesgo principal para la enfermedad cardiovascular. Se realizó una revisión bibliográfica en las bases de datos PubMed, Embase, MEDLINE y Scielo acerca de la terapéutica por denervación renal, hasta mediados del 2014, como versión prometedora de un histórico tratamiento mediante el cual se reduce la activación simpática renal en la hipertensión resistente y en otros estadios de la enfermedad vascular, incluyendo la insuficiencia cardíaca. Se enfocó en la evidencia contemporánea acerca de la utilidad de la denervación renal, se revisó su estado actual y el de los diferentes dispositivos (EnligHTN™ [St Jude Medical, MN, USA], Vessix™ Vascular V2 [Boston Scientific, MA, USA], OneShot™ [Covidien, CA, USA] y PARADISE® [ReCor Medical, CA, USA]). Se consideraron las indicaciones del tratamiento y se analizaron los diferentes problemas aun sin solución (no ha demostrado ningún efecto en la reducción de la morbilidad ni la mortalidad, la principal causa de HTA refractaria es el incumplimiento del paciente y el beneficio de la denervación renal puede ser por la mejor adhesión a la terapia, la reducción de la TA ambulatoria es menor que en la de la consulta) y que necesitan ser resueltos antes de que la denervación renal sea considerada una terapia de elección.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sathananthan J, Watson T, Whitbourn RJ, Stewart JT, Doughty RN, Ormiston R, et al. Renal Sympathetic Denervation: Indications, Contemporary Devices and Future Directions. Interv Cardiol. 2014;6(1):57-69.

  2. Williams B. The year in hypertension. J Am Coll Cardiol. 2009;55:65-73.

  3. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-8.

  4. Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep. 2013;15:134-6.

  5. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23.

  6. Danaei G, Finucane MM, Lin JK. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011;377:568-77.

  7. Mancia G, Fagard R, Narkiewicz K. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219.

  8. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-80.

  9. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012;125:1594-6.

  10. Daugherty SL, Powers JD, Magid DJ. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635-42.

  11. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4121 patients with focus on trial design: the CONVERGE report. Heart. 2012;99(21):1579-87.

  12. Bunte MC, Infante de Oliveira E, Shishehbor MH. Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Inter. 2013;6:1-9.

  13. Ewen S, Ukena C, Bohm M, Mahfoud F. Percutaneous renal denervation: new treatment option for resistant hypertension and more? Heart. 2013;99:1129-34.

  14. Hering D, Walton A, Krum H, Lambert G, Esler M, Schlaich M. Renal artery ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. Int J Cardiol. 2012;159(2): e35-e36.

  15. Geisler BP, Egan BM, Cohen JT. Cost–effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60:1271-7.

  16. Hering D, Lambert E, Marusic P. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-64.

  17. Davis MI, Filion KB, Zhang D. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:231-41.

  18. Ukena C, Mahfoud F, Spies A. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol. 2013;167:2846-51.

  19. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75- 197.

  20. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953;1:403-8.

  21. Doumas M, Faselis C, Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol. 2010;105:570-6.

  22. Krum H, Schlaich M, Whitbourn R. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.

  23. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126:2976-82.

  24. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195–1201.

  25. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.

  26. Bakris GL. Interventional cardiology: indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013;10:434-6.

  27. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903-9.

  28. Davis MI, Filion KB, Zhang D, et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis. J Am Coll Cardiol. 2013;62:231-41.

  29. Hering D, Mahfoud F, Walton AS. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-7.

  30. Hering D, Lambert E, Marusic P. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-64.




2020     |     www.medigraphic.com